Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention DOI Creative Commons
David Tak Wai Lui,

Cheuk‐Kit Wong,

April Ip

et al.

Journal of Endocrinological Investigation, Journal Year: 2023, Volume and Issue: 47(4), P. 895 - 902

Published: Sept. 30, 2023

Abstract Purpose Patients with coronary artery disease have increased fracture risks. P2Y12 inhibitors may impact We compared the risks associated ticagrelor and clopidogrel in dual anti-platelet therapy (DAPT). Methods identified all adults who underwent first-ever percutaneous intervention (PCI) for acute syndrome (ACS) between 2010 2017 from a territory-wide PCI registry Hong Kong. Following 1:1 propensity-score matching baseline characteristics, patients were followed up till event occurrence, death, or 30 June 2022. Outcomes of interest major osteoporotic fractures (MOF) by validated ICD-9-CM codes. Cox proportional hazards regression was used to compute hazard ratio (HR) MOF versus use. Results 3018 users after (mean age: 61.4 years; 84.1% men). Upon median follow-up 6.5 years, 59 119 sustained (annualized risks: 0.34% 0.56%, respectively). Ticagrelor use lower (HR 0.60, 95%CI 0.44–0.83; p = 0.002). Consistent HRs observed over vertebrae, hip upper limbs. Subgroup analyses showed no interaction according age, sex, presence diabetes, chronic kidney prior history. Conclusion Among ACS, DAPT risk clopidogrel. Our results support perspective bone health.

Language: Английский

Incidence of type 2 diabetes before and during the COVID-19 pandemic in Naples, Italy: a longitudinal cohort study DOI Creative Commons
Raffaele Izzo, Daniela Pacella, Valentina Trimarco

et al.

EClinicalMedicine, Journal Year: 2023, Volume and Issue: 66, P. 102345 - 102345

Published: Dec. 1, 2023

BackgroundThe association of COVID-19 with the development new-onset diabetes has been recently investigated by several groups, yielding controversial results. Population studies currently available in literature are mostly focused on type 1 (T1D), comparing patients a SARS-CoV-2 positive test to individuals without COVID-19, especially paediatric populations. In this study, we sought determine incidence 2 (T2D) before and during pandemic.MethodsIn longitudinal cohort analysed followed up over 6-year period using an Interrupted Time Series approach, i.e. 3-years pandemic. We data obtained from >200,000 adults Naples (Italy) January 1st 2017 December 31st 2022. manner, had opportunity compare newly diagnosed T2D (2017–2019) (2020–2022) The key inclusion criteria were age >18-year-old availability for observation; diagnosis excluded. main outcome study was new T2D, as defined International Classification Diseases 10 (ICD-X), including prescription antidiabetic therapies more than 30 days.FindingsA total 234,956 subjects followed-up at least or pandemic included study; among these, 216,498 pre-pandemic years 216,422 years. rate 4.85 (95% CI, 4.68–5.02) per 1000 person-years 2017–2019, vs 12.21 11.94–12.48) 2020–2022, increase about twice half. Moreover, doubling time number diagnoses estimated unadjusted Poisson model 97.12 40.51–153.75) months prepandemic 23.13 16.02–41.59) Interestingly, these findings also confirmed when examining prediabetes.InterpretationOur 200,000 adult participants indicate that significantly higher compared pre-COVID-19 phase. As consequence, epidemiology disease may change terms rates outcomes well public health costs. survivors, prediabetes, require specific clinical programs prevent T2D.FundingThe US National Institutes Health (NIH: NIDDK, NHLBI, NCATS), Diabetes Action Research Education Foundation, Weill-Caulier Hirschl Trusts.

Language: Английский

Citations

19
The relationship between SARS-CoV-2 infection and type 1 diabetes mellitus DOI
Cyril Debuysschere, Magloire Pandoua Nekoua, Enagnon Kazali Alidjinou

et al.

Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: 20(10), P. 588 - 599

Published: June 18, 2024

Language: Английский

Citations

5
Increased prevalence of cardiovascular-kidney-metabolic syndrome conditions during COVID-19: A propensity score-matched study DOI Creative Commons
Valentina Trimarco, Raffaele Izzo, Daniela Pacella

et al.

Diabetes Research and Clinical Practice, Journal Year: 2024, Volume and Issue: 218, P. 111926 - 111926

Published: Nov. 12, 2024

Language: Английский

Citations

5
Unraveling diabetes mellitus incidence post-COVID-19: A comprehensive review of risk factors and implications DOI
Pawan Kumar Patidar,

Devesh Kumar Bandil,

Shruti Garg

et al.

AIP conference proceedings, Journal Year: 2025, Volume and Issue: 3253, P. 030002 - 030002

Published: Jan. 1, 2025

Language: Английский

Citations

0
mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS DOI Creative Commons
Jacob Bar‐Tana

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: March 9, 2025

Post-acute SarS-Cov2 (PASC), Myalgia encephalomyelitis/Chronic fatigue syndrome (ME/CFS) and infection (PAIS) consist of chronic post–acute infectious syndromes, sharing exhaustive fatigue, post exertional malaise, intermittent pain, postural tachycardia neuro-cognitive-psychiatric dysfunction. However, the concerned shared pathophysiology is still unresolved in terms upstream drivers transducers. Also, risk factors which may determine vulnerability/progression to phase remain be defined. In lack a cohesive pathophysiology, syndromes unmet therapeutic needs. 'mTORC1 Syndrome' (TorS) implies an disease entity driven by sustained hyper-activation mammalian target rapamycin C1 (mTORC1), resulting variety aspects Metabolic Syndrome (MetS), non-alcoholic fatty liver disease, obstructive pulmonary some cancers, neurodegeneration other [Bar-Tana Trends Endocrinol Metab 34:135–145, 2023]. TorS offer insight PASC, ME/CFS PAIS drivers, vulnerability treatment options.

Language: Английский

Citations

0
Risk of New-Onset Type 2 Diabetes Among Vaccinated Adults After Omicron or Delta Variant SARS-CoV-2 Infection DOI Creative Commons
Liang En Wee, Jue Tao Lim,

En Yun Loy

et al.

JAMA Network Open, Journal Year: 2025, Volume and Issue: 8(4), P. e252959 - e252959

Published: April 2, 2025

This cohort study estimates the risk of new-onset type 2 diabetes after Delta or Omicron variant SARS-CoV-2 infection among vaccinated adults in Singapore.

Language: Английский

Citations

0
Fulminant Type 1 Diabetes Mellitus With Concomitant Coxsackievirus B6 Antibody Elevation and RNA‐Based COVID‐19 Vaccination: A Case Report and Review of the Literature DOI Creative Commons

Hisaka Minami,

Shinya Furukawa, Teruki Miyake

et al.

Clinical Case Reports, Journal Year: 2025, Volume and Issue: 13(4)

Published: April 1, 2025

ABSTRACT Fulminant type 1 diabetes is a rare but severe condition that can develop rapidly, often in association with viral infections. In this case, coxsackievirus B6 antibody levels were elevated after disease onset, though its significance remains unclear. This highlights the importance of thorough screening fulminant and need for further research to better understand potential contributing factors, including post‐vaccination contexts.

Language: Английский

Citations

0
COVID-19 Vaccination Prior to SARS-CoV-2 Infection Reduced Risk of Subsequent Diabetes Mellitus: A Real-World Investigation Using U.S. Electronic Health Records DOI
Tina Yi Jin Hsieh, Renin Chang, Su‐Boon Yong

et al.

Diabetes Care, Journal Year: 2023, Volume and Issue: 46(12), P. 2193 - 2200

Published: Oct. 18, 2023

Previous studies have indicated a bidirectional correlation between diabetes and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, no investigation has comprehensively explored the potential of disease 2019 (COVID-19) vaccination to reduce risk new-onset in infected individuals.In first cohorts, we compared individuals with SARS-CoV-2 noninfected (N = 1,562,606) using TriNetX database validate findings prior literature. For second cohort, identified 83,829 vaccinated unvaccinated COVID-19 survivors from same period. Diabetes, antihyperglycemic drug use, composite both were defined as outcomes. We conducted Cox proportional hazard regression analysis for estimation ratios (HRs) 95% CIs. Kaplan-Meier was calculate incidence diabetes. Subgroup analyses based on age (18-44, 45-64, ≥65 years), sex (female, male), race (White, Black or African American, Asian), BMI categories (<19.9, 20-29, 30-39, ≥40), sensitivities analyses, dose-response findings.The initial cohort patients had 65% increased (HR 1.65; CI 1.62-1.68) developing relative individuals. In observed that 21% lower comparison 0.79; 0.73-0.86). by sex, age, race, yielded similar results. These consistent sensitivity cross-validation an independent data set TriNetX.In conclusion, this study validates higher SARS-CoV-2-infected counterparts. Furthermore, who received vaccinations experienced reduced diabetes, dose-dependent effect. Notably, protective impact is more pronounced among Black/African American population than other ethnic groups. emphasize imperative widespread mitigate need tailored strategies diverse demographic groups ensure equitable protection.

Language: Английский

Citations

10
Postacute Sequelae of COVID (PASC or Long COVID): An Evidenced-Based Approach DOI Creative Commons
Daniel O. Griffin

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 11(9)

Published: Aug. 27, 2024

Abstract While the acute manifestations of infectious diseases are well known, in some individuals, symptoms can either persist or appear after period. Postviral fatigue syndromes recognized with other viral infections and described coronavirus disease 2019 (COVID-19). We have a growing number individuals that for weeks, months, years. Here, we share evidence regarding abnormalities associated postacute sequelae COVID-19 (PASC) therapeutics. describe physiological biochemical seen reporting PASC. several evidence-based interventions to offer patients. It is expected this understanding mechanisms driving PASC benefits certain therapeutics may not only lead better outcomes those but also potential treating postinfectious sequelae.

Language: Английский

Citations

2
Aberrant STING activation promotes macrophage senescence by suppressing autophagy in vascular aging from diabetes DOI Creative Commons
Huiqing Ding, Quan Zhang,

Rukai Yang

et al.

iScience, Journal Year: 2024, Volume and Issue: 28(1), P. 111594 - 111594

Published: Dec. 13, 2024

Language: Английский

Citations

2